U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06889649) titled 'SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC' on March 03.
Brief Summary: This is a prospective, single-center clinical trial designed to evaluate the safety and efficacy of combining stereotactic ablative body radiotherapy (SABR) with the targeted therapy Axitinib and the immunotherapy Toripalimab in patients with recurrent metastatic renal cell carcinoma (RCC). Patients will receive a treatment regimen consisting of Axitinib, Toripalimab, and comprehensive multi-lesion SABR. The primary endpoint is Progression-Free Survival 1 (PFS1), and secondary endpoints include Progression-Free Survival 2 (PFS2),...